Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jan;10(1):77-85.
doi: 10.1080/14622200701704897.

Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff

Affiliations
Randomized Controlled Trial

Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff

Dorothy K Hatsukami et al. Nicotine Tob Res. 2008 Jan.

Abstract

This preliminary study examined the effects of tobacco-free snuff (intervention, n = 52) compared with no snuff (control, n = 54) for reducing tobacco use among smokeless tobacco (ST) users not interested in quitting. Both groups received behavioral instructions, and intervention subjects received tobacco-free snuff for 8 weeks. Participants were required to reduce their intake by 50% during the first 4 weeks and by 75% during the subsequent 4 weeks. Follow-up occurred at 12 weeks. Significant reductions were observed from baseline to week 8 (end of treatment) for both treatment groups in the amount of ST use (tins/week and dips/day, p<.001); mean urinary cotinine (p<.001); and mean urinary total NNAL, a carcinogen biomarker (p<.001). At week 8 the intervention resulted in a lower mean total NNAL (p = .048). Compared with the control condition, the intervention resulted in a higher percentage of subjects achieving at least a 50% reduction in cotinine (p = .046) and total NNAL (p = .002) at the end of treatment, more quit attempts (p = .030), and a longer mean duration of abstinence (p = .013) through follow-up. An ST reduction intervention incorporating tobacco-free snuff could potentially reduce risk for ST-related disease beyond that achieved with no snuff by increasing the number of patients who achieve significant reductions in carcinogen exposure and, more important, by facilitating tobacco abstinence by increasing quit attempts and abstinence duration.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The effects of tobacco-free snuff and a control condition on amount and frequency of smokeless tobacco use and biomarkers for exposure (total NNAL and cotinine) during the treatment period (baseline to week 8) and at the 12-week follow-up.

References

    1. Agresti A (1990). A categorial data analysis. New York: Wiley.
    1. Behm FM, Schur C, Levin ED, Tashkin DP, & Rose JE (1993). Clinical evaluation of a citric acid inhaler for smoking cessation. Drug and Alcohol Dependence, 31, 131–138. - PubMed
    1. Bolliger CT, Zellweger J-P, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud A, & Sawe U (2000). Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety. British Medical Journal, 321, 329–333. - PMC - PubMed
    1. Cnaan A, Laird N, & Slasor P (1997). Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine, 16, 2349–2380. - PubMed
    1. Etter J, Laszlo E, Zellweger JP, Perrot C, & Perneger TV (2002). Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. Journal of Clinical Psychopharmacology, 22, 487–495. - PubMed

Publication types